trial

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

NCTId NCT06315972
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Not Yet Recruiting
Enrollment 90 (estimated)
Sponsored by LMU Klinikum
Primary completion 2026-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Not Yet Recruiting
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-04
Primary completion
2026-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
clemastine (8 mg/day)

Sponsors

LMU KlinikumLead Sponsor

Sites

0 total

Linked catalysts

1
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schi — primary completion2026-11

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2026-11
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
clemastine (8 mg/day)
drug
lead_sponsor
LMU Klinikum
company
indication
Schizophrenia
indication
Schizophrenia
indication